BioNTech SE ADR [BNTX] stock is trading at $101.72, up 4.01%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BNTX shares have gain 7.64% over the last week, with a monthly amount drifted -0.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $145. Previously, Truist started tracking the stock with Buy rating on January 10, 2025, and set its price target to $172. On December 11, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $170 on the stock. BMO Capital Markets reiterated its Outperform rating. Evercore ISI upgraded its rating to a Outperform and raised its price target to $125 on November 19, 2024. Berenberg started tracking with a Buy rating for this stock on November 19, 2024, and assigned it a price target of $130. In a note dated November 08, 2024, Goldman upgraded an Buy rating on this stock and boosted its target price from $90 to $137.
BioNTech SE ADR [BNTX] stock has fluctuated between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $134 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $101.72 at the most recent close of the market. An investor can expect a potential return of 31.73% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.97B for the trailing twelve months, which represents a drop of -5.51%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.04 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 97.05 points at the first support level, and at 92.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 105.47, and for the 2nd resistance point, it is at 109.23.
Ratios To Look Out For
For context, BioNTech SE ADR’s Current Ratio is 10.18. In addition, the Quick Ratio stands at 10.02 and the Cash Ratio stands at 6.64. Considering the valuation of this stock, the price to sales ratio is 8.24, the price to book ratio is 1.20.
Transactions by insiders
Recent insider trading involved Jeggle Helmut Wolfgang, Director, that happened on May 07 ’25 when 0.15 million shares were purchased. Officer, Richardson Ryan completed a deal on Feb 27 ’25 to buy 26500.0 shares. Meanwhile, Officer Medine GmbH bought 1.0 million shares on Feb 20 ’25.
